The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax
新型抗癌药物 SpiD3 对对伊布替尼或维奈克拉具有耐药性的 CLL 细胞具有细胞毒性
期刊:Hemato
影响因子:
doi:10.3390/hemato5030024
Alexandria P Eiken, Elizabeth Schmitz, Erin M Drengler, Audrey L Smith, Sydney A Skupa, Kabhilan Mohan, Sandeep Rana, Sarbjit Singh, Jayapal Reddy Mallareddy, Grinu Mathew, Amarnath Natarajan, Dalia El-Gamal
